Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full year’s revenue to be around $13.03 billion, close to analysts’ estimates. Its non-GAAP profit of $5.03 per share was 2.3% below analysts’ consensus estimates.

Is now the time to buy VRTX? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from recently launched products in hematology and pain management. Management pointed to disciplined commercial execution and progress in diversifying the revenue base as key themes. CEO Reshma Kewalramani highlighted, “We are well positioned to deliver on the significant opportunities in front of us and drive sustained growth over the long term.” The company credited successful new product launches—particularly in international markets—and deeper penetration across age groups and geographies for cystic fibrosis as primary revenue drivers.

Looking ahead, Vertex’s guidance is underpinned by expectations for growth in its non-cystic fibrosis portfolio, including accelerating adoption of KASJEVY in sickle cell disease and beta thalassemia, and broader uptake of Gernavix for acute pain. Management emphasized ongoing investments to support new launches and pipeline advancement, with CFO Charlie Wagner stating that “growth will be driven by increased volumes of patient infusions and expanded access for newly launched therapies.” The company also outlined near-term regulatory milestones and pipeline readouts, especially in renal diseases and neurology, as strategic priorities for 2026.

Key Insights from Management’s Remarks

Management attributed the quarter’s growth to commercial expansion in cystic fibrosis and momentum in new product launches, while also highlighting pipeline progress, especially in renal diseases.

• CF portfolio expansion: Vertex’s once-daily AlifTrex therapy continued to gain traction, especially among younger patients and in newly reimbursed European and Asia-Pacific markets. Management cited regulatory approvals for broader mutations and strong clinical data in children as differentiators.

• New launches drive diversification: KASJEVY and Gernavix, launched in hematology and pain management, respectively, contributed meaningfully to quarterly growth. KASJEVY’s uptake was supported by expanded reimbursement in both the U.S. and Europe, while Gernavix benefited from increased hospital and retail prescriptions and inclusion in major formularies.

• International momentum: Growth in cystic fibrosis was bolstered by access agreements in over 60 countries and first-time modulator therapy availability for many patients in Italy, Brazil, and Turkey. Management noted that “new geographies and access agreements are key to ongoing expansion.”

• Renal franchise emergence: Vertex’s renal pipeline, anchored by povitacept for IgA nephropathy, made significant progress toward regulatory filings. Management emphasized the importance of monthly auto-injector dosing and ongoing payer engagement as competitive advantages.

• Operational investments: Increased spending in R&D and commercial buildout supported both established franchises and the pipeline, with management citing investments in late-stage clinical programs and sales force expansion as necessary for sustained growth.

Drivers of Future Performance

Vertex expects revenue growth in 2026 to be driven by expanding non-cystic fibrosis franchises and continued strength in its established therapies, with emphasis on new indications and geographies.

• Non-CF therapy ramp-up: Broader access and reimbursement for KASJEVY in the U.S., Europe, and the Middle East, as well as expectations to more than triple Gernavix prescriptions, are set to drive a significant portion of revenue growth. Management believes the expansion of patient eligibility and payer coverage will be critical for these franchises.

• Pipeline milestones ahead: Key regulatory and clinical milestones in 2026, such as the completion of pivotal studies and potential approvals for povitacept in renal diseases and proof-of-concept studies in neurology, are expected to influence future growth. The company is preparing for launches in additional disease areas if results are supportive.

• Investment in commercial infrastructure: Vertex plans to double its field force for pain management, enhance consumer engagement, and continue targeted investments in R&D, which management believes will support both near-term product uptake and long-term pipeline progress. Risks include reimbursement variability and competitive dynamics in newly targeted therapeutic areas.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will focus on (1) the pace and sustainability of prescription growth for Gernavix as patient support programs wind down, (2) regulatory progress and clinical data for povitacept and other renal pipeline candidates, and (3) the success of international launches and reimbursement expansions for both new and established therapies. Updates on payer coverage and real-world adoption in key markets will also be critical markers.

Vertex Pharmaceuticals currently trades at $464.71, in line with $465.02 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.